{"nctId":"NCT00092118","briefTitle":"The Clinical Effects of Montelukast in Patients With Perennial Allergic Rhinitis (0476-265)","startDateStruct":{"date":"2003-10"},"conditions":["Rhinitis, Allergic, Perennial"],"count":1992,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Comparator: Placebo"]}],"interventions":[{"name":"Montelukast","otherNames":[]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Non-smoker with a 2-year documented history of perennial allergic (symptoms that persist throughout the year) rhinitis symptoms and positive allergy testing\n\nExclusion Criteria:\n\n* Medical history of a lung disorder (other than asthma) or a recent upper respiratory tract infection","healthyVolunteers":false,"sex":"ALL","minimumAge":"15 Years","maximumAge":"85 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Change From Baseline in Daytime Nasal Symptoms Score Averaged Over the 6-week Treatment Period in Patients With Perennial Allergic Rhinitis","description":"Mean change from baseline in Daytime Nasal Symptoms score averaged over the 6-week treatment period. The Daytime Nasal Symptoms score was calculated as the average of the 3 individual scores for Congestion, Rhinorrhea, and Sneezing, each rated by patients daily on a 4-point scale \\[Score 0 (best) to 3 (worst)\\].","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.37","spread":null},{"groupId":"OG001","value":"-0.44","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient's Global Evaluation of Allergic Rhinitis at the End of the 6 Week Treatment Period","description":"An evaluation by the patient, administered at the last visit (or upon discontinuation) using a 7-point scale \\[Score 0 (best) to 6 (worst)\\], in answer to a single question regarding the change in symptoms as compared to the beginning of the study.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.42","spread":null},{"groupId":"OG001","value":"2.27","spread":null}]}]}]},{"type":"SECONDARY","title":"Mean Change From Baseline in Rhinoconjunctivitis Quality-of-life Questionnaire (RQLQ) Overall Score After the 6 Week Treatment Period","description":"Patients completed the validated, self-administered RQLQ which included 28 items on a 7-point scale \\[Score 0 (best) to 6 (worst)\\] across 7 domains: activities, sleep, nonnose/eye symptoms, practical problems, nasal symptoms, eye symptoms, and emotional. The scores for each domain were averaged, then scores for the 7 domains were averaged to obtain the overall score.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.69","spread":null},{"groupId":"OG001","value":"-0.84","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":990},"commonTop":[]}}}